Aging cell · 2025
Aerobic Exercise Attenuates Autophagy-Lysosomal Flux Deficits via β2-AR-Mediated ESCRT-III Subunit CHMP4B in Mice With Human MAPT P301L.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bi Shu-Guang, Yu Haitao, Gao Tian-Long, Wu Jia-Jun, Mao Yu-Ming, Gong Juan, Wang Fang-Zhou, Yang Liu, Chen Jia, Lan Zi-Chong, Shen Meng-Ting, Nie Yun-Juan, Chai Gao-Shang
Аннотация
Deficits in the autophagy-lysosomal pathway facilitate intracellular microtubule associated protein tau (MAPT) accumulation in Alzheimer disease (AD). Aerobic exercise (AE) has been recommended as a way to delay and treat AD, but the exact effects and mechanisms have not been fully elucidated. Here, we found that AE (8-week treadmill running, 40 min/day, 5 days/week) alleviated autophagy-lysosomal defects and MAPT pathology through the activation of β2-adrenergic receptors (β2-AR) in MAPT P301L mice. Molecular mechanistic investigations revealed that endosomal sorting complex required for transport (ESCRT) III subunit charged multivesicular body protein 4B (CHMP4B), which is essential for autophagosome-lysosome fusion, was significantly decreased in the cerebral cortex of AD patients and the hippocampus of MAPT P301L mice. AE restored the levels of CHMP4B, which reversed autophagy-lysosomal defects and reduced MAPT aggregation. Inhibition of β2-AR by propranolol (30 mg/kg, intragastric administration 1 h before each AE session) restrained AE-attenuated MAPT accumulation by inhibiting autophagy-lysosomal flux in MAPT P301L mice. Our findings suggest that AE can alleviate autophagosome-lysosome fusion deficits by promoting the β2-AR-RXRα-CHMP4B-ESCRT-III pathway, reducing pathological MAPT aggregation, which also reveals a novel theoretical basis for AE attenuating AD progression.